ABL 001

Drug Profile

ABL 001

Alternative Names: ABL001 - ABL Bio; NOV1501

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ABL Bio
  • Developer ABL Bio; National OncoVenture
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action DLL4 protein inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 18 Sep 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in South Korea (Parenteral) (NCT03292783)
  • 09 Mar 2017 ABL Bio plans a phase I trial for Solid tumours
  • 09 Mar 2017 ABL Bio intends to file an IND application with the US FDA for Solid tumours in 2Q 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top